Kennedy Capital Management LLC Decreases Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Kennedy Capital Management LLC lessened its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 30.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 269,652 shares of the biotechnology company’s stock after selling 117,157 shares during the quarter. Kennedy Capital Management LLC’s holdings in ADMA Biologics were worth $4,625,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in shares of ADMA Biologics by 1.3% in the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company’s stock valued at $865,000 after purchasing an additional 645 shares during the last quarter. Oregon Public Employees Retirement Fund increased its stake in ADMA Biologics by 1.3% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company’s stock valued at $954,000 after purchasing an additional 700 shares in the last quarter. Mutual of America Capital Management LLC raised its holdings in shares of ADMA Biologics by 2.1% in the fourth quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company’s stock worth $614,000 after buying an additional 751 shares during the last quarter. Maryland State Retirement & Pension System lifted its stake in shares of ADMA Biologics by 1.1% during the fourth quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company’s stock worth $1,365,000 after buying an additional 897 shares during the period. Finally, GAMMA Investing LLC grew its holdings in shares of ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 967 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

ADMA opened at $19.40 on Friday. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 12-month low of $5.91 and a 12-month high of $23.64. The firm has a 50 day moving average of $17.78 and a two-hundred day moving average of $18.16. The firm has a market capitalization of $4.59 billion, a PE ratio of 69.29 and a beta of 0.53.

Analyst Ratings Changes

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 target price on shares of ADMA Biologics in a research note on Tuesday, March 4th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.